In our pursuit of cost-effectiveness, are we overlooking a crucial factor?
Our recent publication, “Real-world service costs for neovascular-AMD clinics in the United Kingdom: Structured literature review and scenario analysis,” featured in Current Medical Research and Opinion, highlights significant strain costs affecting nAMD clinics, often ignored in traditional cost-effectiveness analyses.
In our scenario analysis, while Drug A might seem cheaper with a lower upfront cost (£10), the associated strain costs (£13,115) tell a different story compared to Drug B (£100 upfront with no additional strain costs).
What does this mean?
- Drug A: Lower initial cost but significant long-term strain costs.
- Drug B: Higher initial cost but no additional strain costs.
Impact on Decision-Making: Evaluating options requires considering not just immediate costs such as drug costs, but also the broader economic impact on the service as a whole. Incorporating strain costs into Health Technology Assessments (HTA) offers a more comprehensive view, ensuring sustainable and efficient healthcare delivery.
Reach out to Medialis Ltd to shift towards more holistic evaluations that consider all costs, leading to better decision-making and improved patient care. Join the conversation and share your insights on integrating these findings into our practices.
#nAMD #HealthcareEconomics #CostEffectiveness #HTA #HealthcareInnovation
Link: https://www.linkedin.com/feed/update/urn:li:share:7218927349344456704/?actorCompanyId=11809093